Synthetic peptide, and cosmetic composition or pharmaceutical composition and application thereof
US-2024352069-A1 · Oct 24, 2024 · US
US2023404920A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023404920-A1 |
| Application number | US-202118036018-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 11, 2021 |
| Priority date | Nov 11, 2020 |
| Publication date | Dec 21, 2023 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to calibrated (per)fluorocarbon nanodroplets comprising an outer layer and an inner core, said outer layer comprising a biocompatible fluorinated surfactant and said inner core comprising a (per)fluorocarbon. The invention further relates to a method of preparation of said calibrated (per)fluorocarbon nanodroplets through microfluidic technique, and to their use for in vivo or in vitro diagnostic and/or for therapy.
Opening claim text (preview).
1 ) A nanodroplet comprising an outer layer and an inner core, said outer layer comprising a biocompatible fluorinated surfactant and said inner core comprising a fluorocarbon, characterized in that the molar ratio between said biocompatible surfactant and said fluorocarbon is higher than 0.06, wherein said biocompatible fluorinated surfactant is selected from (A) an amphiphilic dendrimer (Dendri-TAC) of generation n comprising: a hydrophobic central core of valence 2 or 3; generation chains attached to each respective open end of the central core and branching around the core; and a hydrophilic terminal group at the end of each generation chain; wherein n is an integer from 0 to 12 and identifies the hydrophilic terminal group comprising: a mono-, oligo- or polysaccharide residue, a cyclodextrin residue, a peptide residue, a tris(hydroxymethyl)aminomethane (Tris), or a 2-amino-2-methylpropane-1,3-diol; the hydrophobic central core is a group of formula (Ia) or (Ib) wherein: W is R F or a group selected from W 0 , W 1 , W 2 or W 3 : R F is a C 4 -C 10 perfluoroalkyl or a C 1 -C 24 alkyl group, R H is a C 1 -C 24 alkyl group, p is 0, 1, 2, 3 or 4; q is 0, 1, 2, 3 or 4; L is a linear or branched C 1 -C 12 alkylene group, optionally interrupted by one or more —O—, —S—, Z is C(═O)NH or NHC(═O), R is a C 1 -C 6 alkyl group, and e is at each occurrence independently selected from 0, 1, 2, 3 or 4, (B) an amphiphilic linear oligomer (F-TAC) of formula II wherein: n is the number of repeating Tris units (n=DPn is the average degree of polymerization), wherein the term Tris indicates the tris(hydroxymethyl)aminomethane unit, and i is the number of carbon atoms in the fluoroalkyl chain or a mixture thereof. 2 ) The nanodroplet according to claim 1 , wherein said amphiphilic dendrimer Dendri-TAC is selected from the group comprising the following compounds of formula IA and of formula IB 3 ) The nanodroplet according to claim 1 , wherein said amphiphilic linear oligomer F-TAC is selected from the group comprising the following compounds of formula IIA and of formula IIB 4 ) The nanodroplet according to claim 1 , wherein said fluorocarbon is a perfluorocarbon. 5 ) The nanodroplet according to claim 1 , wherein said molar ratio between said biocompatible fluorinated surfactant and said fluorocarbon is higher than 0.07. 6 ) An aqueous suspension comprising a nanodroplet according to claim 1 . 7 ) An aqueous suspension comprising a plurality of nanodroplets according to claim 1 , wherein said nanodroplets have a z-average diameter comprised between 100 nm and 1000 nm and a polydispersity lower than 0.25. 8 ) The aqueous suspension according to claim 6 further comprising trehalose. 9 ) A method for the preparation of an aqueous suspension of calibrated fluorocarbon nanodroplets, said method comprising the steps of: a) Preparing an aqueous phase; b) Preparing an organic phase, wherein i) said aqueous phase comprises a biocompatible fluorinated surfactant selected from a Dendri-TAC, a F-TAC or a mixture thereof and the organic phase comprises a fluorocarbon or ii) said organic phase comprises a biocompatible fluorinated surfactant selected from a Dendri-TAC, a F-TAC or a mixture thereof and a fluorocarbon. c) Injecting said aqueous phase into a first inlet and said organic phase into a second inlet of a microfluidic cartridge, thereby mixing said aqueous phase and said organic phase in a mixing device of the microfluidic cartridge to obtain an aqueous suspension of calibrated fluorocarbon nanodroplets, and d) Collecting the aqueous suspension of calibrated fluorocarbon nanodroplets from the exit channel of the microfluidic cartridge. 10 ) The method according to claim 9 , wherein said aqueous phase comprises a biocompatible fluorinated surfactant selected from a Dendri-TAC, a F-TAC or a mixture thereof and said organic phase comprises a fluorocarbon. 11 ) The method according to claim 9 , wherein said fluorocarbon is a perfluorocarbon. 12 ) The method according to claim 11 , wherein said perfluorocarbon is selected from perfluoropentane, perfluorohexane, perfluorooctylbromide or a mixture thereof. 13 ) The method according to claim 9 , wherein the ratio between the volume of said aqueous phase and the volume of said organic phase is comprised between 1:1 to 5:1. 14 ) The method according to claim 9 , further comprising additional step e) wherein said collected suspension of calibrated fluorocarbon nanodroplets is diluted with an aqueous liquid. 15 ) The method according to claim 14 , wherein said aqueous liquid is water. 16 ) (canceled) 17 ) (canceled) 18 ) (canceled) 19 ) An aqueous suspension comprising a plurality of calibrated fluorocarbon nanodroplets obtainable by a method of preparation comprising the steps of: a) Preparing an aqueous phase; b) Preparing an organic phase, wherein i) said aqueous phase comprises a biocompatible fluorinated surfactant, selected from Dendri-TAC, F-TAC or a mixture thereof, and the organic phase comprises a fluorocarbon or ii) said organic phase comprises a biocompatible fluorinated surfactant, selected from selected from Dendri-TAC, F-TAC or a mixture thereof and a fluorocarbon. c) Injecting said aqueous phase into a first inlet and said organic phase into a second inlet of a microfluidic cartridge, thereby mixing said aqueous phase and said organic phase in a mixing device of the microfluidic cartridge to obtain an aqueous suspension of calibrated fluorocarbon nanodroplets, and d) Collecting the aqueous suspension of calibrated fluorocarbon nanodroplets from the exit channel of the microfluidic cartridge, wherein said nanodroplets have a z-average diameter comprised between 100 nm and 1000 nm and a polydispersity lower than 0.25. 20 ) (canceled) 21 ) A method of diagnostic and/or therapeutic treatment comprising administering the aqueous suspension according to claim 6 to a patient.
Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title
Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title
Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids · CPC title
Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title
Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.